This article is more than 5 years old. Information may no longer be current.
FDA OKs Stelara for ulcerative colitis, common drugs disrupt microbiome — top stories in gastroenterology
News that Stelara — a treatment that has been commercially available to treat Crohn’s disease for more than 3 years — was approved by the FDA to treat ulcerative colitis was one of the top stories in gastroenterology last week.
Another top story included study results presented at United European Gastroenterology Week that showed 18 common drug categories were associated with changes in gut microbiome that could increase risks for infection, obesity and other conditions.
FDA approves Stelara for ulcerative colitis
The FDA approved Stelara for the treatment of adults with moderately to severely active ulcerative colitis, according to a press release from the manufacturer. Read more.
Common medications linked to changes in gut microbiome
A group of commonly used drug categories have a significant impact on the makeup of the gut microbiome, which could increase the risk for infection, obesity and other conditions, according to study results presented at UEG Week. Read more.
Guest Commentary: Physicians must rise to the need for younger CRC screening
Paul J. Limburg, MD, a professor of medicine in the College of Medicine at the Mayo Clinic, discusses the need for increased awareness of colorectal cancer incidence among the younger population and the newer methods available for screening within this newly at-risk group. Read more.
Monday Night IBD offers GIs, experts a new way to discuss cases
The phrase “Monday night” often instills images of professional football played under the lights in front of national audiences. However, the phrase “Monday night” has a different meaning for some experts in inflammatory bowel disease. Instead of scrambling for their remotes or a TV to watch the game, many are dashing for their phones or computers to buckle down and participate in a conversation. Read more.
‘Super donor’ FMT effective in IBS
Fecal microbiota transplantation is an effective treatment for patients with irritable bowel syndrome, but the fecal sample must come from a “super donor,” according to study results presented at UEG Week. Read more.